(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/138507 A1

(51) International Patent Classification:
*A61K 31/5025* (2006.01) *A61P 35/00* (2006.01)
*A61P 31/12* (2006.01) *A61P 1/16* (2006.01)

(21) International Application Number:
PCT/US2006/023394

(22) International Filing Date: 15 June 2006 (15.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/691,497 17 June 2005 (17.06.2005) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LIN, Kai** [US/US]; 153 Hawthorne Road, Waltham, MA 02451 (US). **WEIDMANN, Beat** [US/US]; 47 Bacon Street, Winchester, MA 01890 (US). **ZIMMERMANN, Kaspar** [CH/CH]; Am Chatzebach 4, CH-4104 Oberwil BL (CH).

(74) Agent: **SAVITSKY, Thomas**; Novartis, Corporate Intellectual Property, One Health Plaza, Bldg. 104, East Hanover, NJ 07936 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2006/138507 A1

(54) Title: USE OF SANGLIFEHRIN IN HCV

(57) Abstract: The present invention discloses the use of a macrolide compound such as a sanglifehrin for the treatment and prevention of hepatitis C and related diseases such as liver fibrosis, liver cirrhosis and hepatocellular carcinoma.